Frost Radar™: Digital Biomanufacturing of Viral Vectors, 2025
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
11-Nov-2025
Global
Technology Research
DB4F-01-00-00-00
HC_2025_34078
Viral vectors are a critical part of gene therapies and genetic medicines, which are the cornerstone of precision medicines to cure rare diseases, cancers, and genetic disorders. Traditional bioprocessing, however, is tedious, less flexible, batch-based, and heavily manual; as a result, manufacturing processes involve high costs, scalability issues, and variability. Digital biomanufacturing represents a transformational shift in the development of viral vectors. The convergence of digital technologies and biomanufacturing makes the process more resilient, efficient, and adaptive. The demand for digital viral vector manufacturing is being driven by the intense competition in gene and cell therapies. Because of the one-time curative potential of these treatments, early adopters can gain the greatest patient share, while late entrants face a declining market. Because early launches can draw investors and gain a competitive advantage, speed and timeline adherence are crucial. Digital tools make the process more productive and scalable.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
Andelyn Biosciences, US
Ascend Ltd, US
Cytiva, US
Dyno, US
FUJIFILM Biotechnologies, US
Lonza, Switzerland
Oxford Biomedica PLC, UK
PackGene Biotech, US
Repligen Corporation, US
Revvity, US
Thermo Fisher Scientific, US
VIRALGEN, Spain
Significance of Being on the Frost Radar
CEO’s Growth Team
Investors
Customers
Board of Directors
Speak directly with our analytics experts for tailored recommendations.
Recent related Pharmaceuticals research
19 Nov 2026 | Global | Technology Research
Programmable Vaccines: AI-Designed Antigens and Next-Generation Rapid Platforms
Traditional vaccine development is an empirical, time-consuming process that often leads to a high failure rate. With the proven clinical success of RNA vaccines, there has been a focus on accelerating the development of vaccines to address the growing incidence of infectious diseases and emerging p...
17 Nov 2026 | Global | Frost Radar
Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026
Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...
16 Oct 2026 | Global | Technology Research
Innovations and Growth Opportunities in Precision Therapeutics, AI-Enabled Discovery and Bioengineering, Regenerative Medicine, and Next-Generation Vaccine Platforms
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufactu...
15 Oct 2026 | Global | Frost Radar
Frost Radar™: US and European Mammalian Contract Development and Manufacturing Organizations, 2026
The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As mo...
23 Sep 2026 | Global | Technology Research
Programmable Epigenome Editing for Disease Reversal
Programmable epigenome editing is developing as a distinct approach to controlling gene activity without changing the underlying DNA sequence. This report examines the landscape from the core editing technologies and delivery systems through the companies, academic programs and therapeutic applicati...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.